FDA-Sponsor Interaction Could Increase Post-Pandemic With Virtual, In-Person Options
Scott Gottlieb says that some meetings should remain in-person, but with virtual options proven effective, the FDA could offer more opportunities to talk to sponsors.
You may also be interested in...
Some sponsors appear to be growing antsy to meet with agency staff and advisory committees in-person, but CDER continues to schedule only virtual meetings.
A workshop broadcast from White Oak was a shift from the fully virtual meetings held since the height of the COVID-19 pandemic and may be a step toward once again staging public events there.
Virtual meetings proved successful, and could be allowed again when the next round of user fee reauthorization talks convene.